Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-445-5704
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 million
Profitability
Miscellaneous
Employees90
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions
What is Xeris Pharmaceuticals' stock symbol?
Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."
How were Xeris Pharmaceuticals' earnings last quarter?
Xeris Pharmaceuticals Inc (NASDAQ:XERS) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.34. The company had revenue of $0.31 million for the quarter, compared to analysts' expectations of $0.20 million. Xeris Pharmaceuticals had a negative net margin of 4,876.50% and a negative return on equity of 107.65%. View Xeris Pharmaceuticals' Earnings History.
When is Xeris Pharmaceuticals' next earnings date?
What price target have analysts set for XERS?
2 analysts have issued 1 year price objectives for Xeris Pharmaceuticals' stock. Their predictions range from $18.00 to $27.00. On average, they anticipate Xeris Pharmaceuticals' share price to reach $22.50 in the next twelve months. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.
What is the consensus analysts' recommendation for Xeris Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.
What are Wall Street analysts saying about Xeris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019)
- 2. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)
Has Xeris Pharmaceuticals been receiving favorable news coverage?
Media stories about XERS stock have been trending somewhat negative on Friday, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Xeris Pharmaceuticals.
Are investors shorting Xeris Pharmaceuticals?
Xeris Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totalling 2,450,000 shares, an increase of 17.2% from the August 15th total of 2,090,000 shares. Based on an average daily trading volume, of 196,700 shares, the days-to-cover ratio is presently 12.5 days. Approximately 11.0% of the company's stock are sold short. View Xeris Pharmaceuticals' Current Options Chain.
Who are some of Xeris Pharmaceuticals' key competitors?
Some companies that are related to Xeris Pharmaceuticals include Athenex (ATNX), G1 Therapeutics (GTHX), Dova Pharmaceuticals (DOVA), Amneal Pharmaceuticals (AMRX), CannTrust (CNTTF), Endo International (ENDP), Cara Therapeutics (CARA), Omeros (OMER), Organogenesis (ORGO), Principia Biopharma (PRNB), Rhythm Pharmaceuticals (RYTM), Vanda Pharmaceuticals (VNDA), Wave Life Sciences (WVE), Kura Oncology (KURA) and Stoke Therapeutics (STOK).
What other stocks do shareholders of Xeris Pharmaceuticals own?
Who are Xeris Pharmaceuticals' key executives?
Xeris Pharmaceuticals' management team includes the folowing people:
- Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
- Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
- Mr. John P. Shannon, Exec. VP & COO (Age 57)
- Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
- Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
When did Xeris Pharmaceuticals IPO?
(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.
How do I buy shares of Xeris Pharmaceuticals?
Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Xeris Pharmaceuticals' stock price today?
One share of XERS stock can currently be purchased for approximately $9.00.
How big of a company is Xeris Pharmaceuticals?
Xeris Pharmaceuticals has a market capitalization of $242.88 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.
What is Xeris Pharmaceuticals' official website?
How can I contact Xeris Pharmaceuticals?
Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]
MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
